15^th World Congress on Endocrinology & Diabetes September 20-21, 2019 | Prague, Czech Republic

Dr.Panthi has completed an internal medicine residency from Jersey City Medical Center, NJ, USA. She has been working as a hospitalist in Baptist Hospital Desoto, MS, USA. She has a special interest in in-hospital diabetes management and diabetic ketoacidosis

Prevalence of patients with both diabetes and COPD is high in the US population. Steroid-induced hyperglycemia frequently poses a challenge in managing these patients in the hospital during COPD exacerbation. There have not been studies to look into how this impacts diabetic medications on discharge. We did a retrospective chart review of diabetic patients admitted to a community hospital for COPD exacerbation in the year 2018. A total of 363 patients with a mean age of 67 (± 11.8) was studied. HbA1c was available for 178 patients, of whom 62.3% had HbA1c more than 7%. There was an increase in blood sugar (BG) from mean 219mg/dl on admission to mean 241mg/dl after steroid administration (P 0.001 paired T-test), but no increase in blood sugar on discharge day (mean200mg/dl) compared to the admission one. There was no difference in increases in blood sugar in patients with HbA1c >7% compared to one with <7% (P 0.88, Student T-test). Diabetic medication changes on discharge as compared to the admission were noted. Medication escalation in this context was defined as any increase or addition of non-insulin or insulin medication on discharge. Of all patients, 4% had either increase or a new start of non-insulin diabetic medications. The 6.1% of all patients were newly started on insulin regimens and 5.8% of patients had pre-existing insulin dose increased. Overall, medication escalation was seen in 21.8% and 19.1% of patients with hemoglobin A1c of >7% and <7% respectively (OR 1.18, 95% CI 0.55 – 2.51). Of the patients with HbA1c <7% (N = 67), 3% had an increase in pre-existing insulin regimen, and 9% had a new start of insulin regimen

Dr Kandarp Thakkar has expertise in evaluation and passion in improving the health and wellbeing. He has done his doctor of medicine (MD) in Pharmacology from Ahmedabad, India. He has been associated with Intas Pharmaceuticals with more than a year as Medical Advisor

Statement of the Problem: Benign prostatic hyperplasia is a common problem in aging males. As studies suggest that at the age of 40, 5 to 10% of men have prostate enlargement whereas at 80 years, prevalence is as high as 80%. However prostate size directly correlates with severity of symptoms like patients with huge palpable prostate may be asymptomatic whereas those with small prostate may have severe symptoms. However, there are not many studies done in diabetic BPH patients. The purpose of this study is to determine treatment strategy in diabetic BPH patients among clinicians. Methodology & Theoretical Orientation: Study was conducted using preformed questionnaires regarding management approach of Diabetic BPH patients in day to day practice. Questionnaires were administered to clinicians (Diabetologist, Endocrinologist, Physicians) at two different national conferences in India. rnFindings: Total of 88 clinicians across India completed the survey. rn35 % of clinicians reported prevalence of Diabetic BPH patient 20-30 % in their practice. More than 60% of clinicians manage these patients by themselves instead of referring them to urologist. More than half of the clinicians suggest ultrasound to check size of the prostate in all patients.42% of clinicians preferred prescribing Tamsulosin with Finasteride due to its safety & efficacy in diabetic BPH patients.rnConclusion & Significance: Diabetic patients with enlarged prostate having Benign prostatic hyperplasia combination therapy of alpha blocker & 5-ê­¤ reductase inhibitor is preferred among clinicians.rn